Base Editing Breaks Through in the Clinic — Beam Therapeutics 2026 Pipeline

Beam Therapeutics is advancing in vivo base editing — chemical single-base conversion (A→G or C→T) with no double-strand DNA breaks — across three indications. Base editing is positioned as a "safer CRISPR": it avoids the indels and chromosomal rearrangements that cut-based CRISPR-Cas9 can produce. All three programs use lipid nanoparticle (LNP) delivery to the liver (PKU, AATD) or an ex vivo approach (sickle cell).

BEAM-304 — Phenylketonuria (PKU)

• FDA cleared the BEAM-304 IND on June 18, 2026.
• Adenine base editor delivered to the liver by LNP, correcting PAH gene mutations; the program first targets the common R408W variant, with plans for additional mutation-specific editors.
• Preclinical PKU mouse models showed robust on-target liver editing and normalization of plasma phenylalanine at clinically relevant doses.
• Planned Phase 1/2 will assess safety, tolerability, blood phenylalanine reduction, and dietary liberalization (PKU patients otherwise need a lifelong restricted diet).
• Source: CRISPR Medicine News, Gorm Palmgren, June 22, 2026.

BEAM-302 — Alpha-1 Antitrypsin Deficiency (AATD)

• Announced the first-ever genetic correction in AATD patients — an in vivo liver-targeting LNP base editor correcting the PiZ (Z-AAT) mutation.
• Single IV doses (15–60 mg) produced dose-dependent, durable increases in total AAT and decreases in Z-AAT, with only minor adverse events.
• The highest-dose cohort reached circulating AAT levels sufficient to halt disease progression.

BEAM-101 — Sickle Cell Disease

• Ex vivo base editing that eliminates the need for busulfan chemotherapy (a major conditioning toxicity of prior approaches).
• Treated patients showed a >90% reduction in the disease-related protein within four weeks, sustained at least 36 weeks.
• Note: a sickle-cell patient death was reported in a Beam base-editing study; reporting attributed it to disease/conditioning context rather than the editor itself — durability and safety remain under active monitoring.

Verve Therapeutics (Beam's base-editing licensee) — Cardiovascular

• VERVE-102 (familial hypercholesterolemia, PCSK9): Phase 1b dose-dependent response, no serious adverse events, maximum LDL reduction of 69% in the highest-dose cohort; Phase 2 planned.
• VERVE-201 (ANGPTL3): first patient dosed for homozygous familial hypercholesterolemia.
• When VERVE-101 showed thrombocytopenia, it was attributed to the LNP vehicle, not the base-editing machinery.

Why It Matters

By 2026, base editing is de-risked across multiple indications (AATD, familial hypercholesterolemia, sickle cell), per analyst commentary. The single-base, no-cut mechanism plus LNP-to-liver delivery is becoming the dominant in vivo template for correcting (not just knocking out) point mutations — complementing Intellia's knockout approach and Liu's prime editing.

Source

• CRISPR Medicine News (Gorm Palmgren), "Clinical: Beam Advances Base Editing For PKU," June 22, 2026.
• BioSpace (Shawna Williams), "Safer CRISPR: Base Editing Breaks Through in the Clinic as Beam, Verve Advance" (AATD/sickle cell/Verve figures).